Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GLSI - US3968791083 - Common Stock

10.74 USD
+0.34 (+3.27%)
Last: 12/17/2025, 8:00:02 PM
10.55 USD
-0.19 (-1.77%)
After Hours: 12/17/2025, 8:00:02 PM
Fundamental Rating

2

GLSI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. GLSI has a great financial health rating, but its profitability evaluates not so good. GLSI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GLSI has reported negative net income.
GLSI had a negative operating cash flow in the past year.
In the past 5 years GLSI always reported negative net income.
In the past 5 years GLSI always reported negative operating cash flow.
GLSI Yearly Net Income VS EBIT VS OCF VS FCFGLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

GLSI has a worse Return On Assets (-511.58%) than 96.60% of its industry peers.
GLSI has a worse Return On Equity (-891.34%) than 80.34% of its industry peers.
Industry RankSector Rank
ROA -511.58%
ROE -891.34%
ROIC N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
GLSI Yearly ROA, ROE, ROICGLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

GLSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLSI Yearly Profit, Operating, Gross MarginsGLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLSI has more shares outstanding
Compared to 5 years ago, GLSI has more shares outstanding
GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLSI Yearly Shares OutstandingGLSI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GLSI Yearly Total Debt VS Total AssetsGLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 10.20 indicates that GLSI is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 10.20, GLSI belongs to the best of the industry, outperforming 82.42% of the companies in the same industry.
There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.2
ROIC/WACCN/A
WACCN/A
GLSI Yearly LT Debt VS Equity VS FCFGLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

GLSI has a Current Ratio of 2.35. This indicates that GLSI is financially healthy and has no problem in meeting its short term obligations.
GLSI has a worse Current ratio (2.35) than 72.59% of its industry peers.
A Quick Ratio of 2.35 indicates that GLSI has no problem at all paying its short term obligations.
GLSI's Quick ratio of 2.35 is on the low side compared to the rest of the industry. GLSI is outperformed by 70.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35
GLSI Yearly Current Assets VS Current LiabilitesGLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

GLSI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -82.50%.
EPS 1Y (TTM)-82.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLSI will show a decrease in Earnings Per Share. The EPS will decrease by -7.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.93%
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLSI Yearly Revenue VS EstimatesGLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M
GLSI Yearly EPS VS EstimatesGLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
Also next year GLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLSI Price Earnings VS Forward Price EarningsGLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLSI Per share dataGLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

GLSI's earnings are expected to decrease with -7.71% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLSI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (12/17/2025, 8:00:02 PM)

After market: 10.55 -0.19 (-1.77%)

10.74

+0.34 (+3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)04-13 2026-04-13
Inst Owners9.52%
Inst Owner Change-7.92%
Ins Owners52.5%
Ins Owner Change0.24%
Market Cap148.75M
Revenue(TTM)N/A
Net Income(TTM)-19.48M
Analysts82.5
Price Target42.84 (298.88%)
Short Float %24.47%
Short Ratio10.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.12%
Min EPS beat(2)-22.55%
Max EPS beat(2)0.3%
EPS beat(4)1
Avg EPS beat(4)-52.29%
Min EPS beat(4)-184.78%
Max EPS beat(4)0.3%
EPS beat(8)4
Avg EPS beat(8)-24.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 68.08
P/tB 68.08
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -511.58%
ROE -891.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z 10.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y6.93%
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.37%
OCF growth 3YN/A
OCF growth 5YN/A

GREENWICH LIFESCIENCES INC / GLSI FAQ

What is the fundamental rating for GLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLSI.


What is the valuation status for GLSI stock?

ChartMill assigns a valuation rating of 0 / 10 to GREENWICH LIFESCIENCES INC (GLSI). This can be considered as Overvalued.


What is the profitability of GLSI stock?

GREENWICH LIFESCIENCES INC (GLSI) has a profitability rating of 0 / 10.